Cyclacel receives notification of deficiency from nasdaq regarding timely filing of quarterly report on form 10-q

Berkeley heights, n.j., nov. 28, 2023 (globe newswire) -- cyclacel pharmaceuticals, inc. (nasdaq: cycc, nasdaq: cyccp; "cyclacel" or the "company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that it received a notice of non-compliance from nasdaq stock market llc (“nasdaq”) on november 21, 2023 stating that, as a result of not having timely filed its quarterly report on form 10-q for the quarter ended september 30, 2023, the company is not in compliance with nasdaq listing rule 5250(c)(1), which requires timely filing of periodic financial reports with the u.s. securities and exchange commission. this notice has no immediate effect on the listing or trading of the company's securities on nasdaq.
CYCC Ratings Summary
CYCC Quant Ranking